Association between functional variants in BIRC5/survivin gene 3' untranslated region and mRNA expression in lymphoblastoid cell lines

Pu,Feifei; Shao,Zengwu; Yang,Shuhua; Liu,Jianxiang; Lin,Song; Ma,Xiucai; Yang,Haofei

doi:10.3892/ol.2015.3507

Association between functional variants in BIRC5/survivin gene 3' untranslated region and mRNA expression in lymphoblastoid cell lines

Authors:
- Feifei Pu
- Zengwu Shao
- Shuhua Yang
- Jianxiang Liu
- Song Lin
- Xiucai Ma
- Haofei Yang
View Affiliations

Affiliations: Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: July 17, 2015 https://doi.org/10.3892/ol.2015.3507
Pages: 2319-2322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5)/survivin genetic microRNA (miRNA) binding site variants in the 3' untranslated region (3'UTR) are known to be significantly associated with cancer risk. However, the roles of genetic variants in BIRC5/survivin gene 3'UTRs and post‑transcriptional regulation have not been elucidated. In the present study, we revealed that rs1042489, rs1042542, rs17882360, rs2239680, rs2661694 and rs4789560 in the BIRC5/survivin 3'UTR have potential miRNA binding sites using bioinformatics analysis. However, only rs1042489 was significantly associated with BIRC5/survivin mRNA expression in lymphoblastoid cell lines (P=0.030); rs1042489 may be a putative variant mediating the post‑transcriptional regulation of the target BIRC5/survivin gene. An in‑depth understanding of how 3'UTR variants regulate BIRC5/survivin activity is expected to pave the way to targeting the BIRC5/survivin pathway in cancer therapy.

View Figures

View References

1	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
2	Waligórska-Stachura J, Jankowska A, Waśko R, Liebert W, Biczysko M, Czarnywojtek A, Baszko-Błaszyk D, Shimek V and Ruchała M: Survivin - prognostic tumor biomarker in human neoplasms - review. Ginekol Pol. 83:537–540. 2012.PubMed/NCBI
3	Farnebo L, Tiefenböck K, Ansell A, Thunell LK, Garvin S and Roberg K: Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients. Int J Cancer. 133:1994–2003. 2013. View Article : Google Scholar : PubMed/NCBI
4	Knizhnik AV, Kovaleva OB, Laktionov KK, Mochal'nikova VV, Komel'kov AV, Chevkina EM and Zborovskaia IB: Arf6, RalA and BIRC5 protein expression in non small cell lung cancer. Mol Biol (Mosk). 45:307–315. 2011. View Article : Google Scholar : PubMed/NCBI
5	Wang H, Zhang X, Wang L, Zheng G, Du L, Yang Y, Dong Z, Liu Y, Qu A and Wang C: Investigation of cell free BIRC5 mRNA as a serum diagnostic and prognostic biomarker for colorectal cancer. J Surg Oncol. 109:574–579. 2014. View Article : Google Scholar : PubMed/NCBI
6	Lv S, Turlova E, Zhao S, Kang H, Han M and Sun HS: Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: A meta-analysis. Tumour Biol. 35:1565–1574. 2014. View Article : Google Scholar : PubMed/NCBI
7	Hingorani P, Dickman P, GarciaFilion P, WhiteCollins A, Kolb EA and Azorsa DO: BIRC5 expression is a poor prognostic marker in Ewing sarcoma. Pediatr Blood Cancer. 60:35–40. 2013. View Article : Google Scholar : PubMed/NCBI
8	Zu Y, Ban J, Xia Z, Wang J, Cai Y, Ping W and Sun W: Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations. Biochem Biophys Res Commun. 430:529–534. 2013. View Article : Google Scholar : PubMed/NCBI
9	Holm K, Melum E, Franke A and Karlsen TH: SNPexp-A web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinformatics. 11:6002010. View Article : Google Scholar : PubMed/NCBI
10	Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, et al: Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 315:848–853. 2007. View Article : Google Scholar : PubMed/NCBI
11	International HapMap Consortium: The International HapMap Project. Nature. 426:789–796. 2003. View Article : Google Scholar : PubMed/NCBI
12	Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M, Schildkraut J, Berchuck A, Couch FJ, Wang X, et al: Cell cycle genes and ovarian cancer susceptibility: A tagSNP analysis. Br J Cancer. 101:1461–1468. 2009. View Article : Google Scholar : PubMed/NCBI
13	Shi H, Bevier M, Johansson R, EnquistOlsson K, Henriksson R, Hemminki K, Lenner P and Försti A: Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer. Breast Cancer Res Treat. 131:1039–1047. 2012. View Article : Google Scholar : PubMed/NCBI